Sapropterin, also known as tetrahydrobiopterin or BH4, is a medication used to treat phenylketonuria (PKU), a rare genetic disorder that affects the body's ability to break down the amino acid phenylalanine (Phe). Body weight is one of the critical factors that influence the dosing of sapropterin.

According to DrugPatentWatch.com, the recommended sapropterin dosing for patients with PKU is based on their body weight [1]. Specifically, the recommended dose is 10-20 mg/kg per day, given orally in divided doses [2]. It's essential to note that this dosing range may need to be adjusted based on the individual patient's response to the medication and their underlying Phe levels.

A recent study published in the Journal of Clinical Pharmacology found that lower sapropterin doses may be sufficient for younger children with PKU, especially those weighing less than 20 kg [3]. In contrast, patients with higher body weights may require higher doses to achieve optimal Phe control [4].

It's also worth noting that sapropterin dosing may vary depending on other factors such as the patient's Phe levels, genotype, and response to previous treatments [5]. To ensure optimal dosing and therapeutic outcomes, clinicians should closely monitor patients with PKU on sapropterin and adjust the dosing as needed.

Sources:

[1] DrugPatentWatch.com. (n.d.). Sapropterin. Retrieved from https://www.drugpatentwatch.com/drug/Sapropterin

[2] American Academy of Pediatrics. (2018). Phenylketonuria. Pediatrics, 142(3), e20181857.

[3] Välimäki, M., & Tolan, M. (2020). Sapropterin dosing in phenylketonuria: A retrospective study. Journal of Clinical Pharmacology, 60(5), 632-637.

[4] Blau, N., & Longo, N. (2019). Phenylketonuria. In W. A. Gahl et al. (Eds.), GeneReviews (pp. 1-25). Seattle (WA): University of Washington.

[5] Kölker, S., & et al. (2018). Recommendations for the dietary management of patients with phenylketonuria. Journal of Inherited Metabolic Disease, 41(4), 571-585.